DOCSLIB.ORG

Ulcerative Colitis Outcomes Research in Japan

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ulcerative Colitis Outcomes Research in Japan Open access Protocol BMJ Open: first published as 10.1136/bmjopen-2019-030134 on 8 September 2019. Downloaded from Ulcerative colitis outcomes research in Japan: protocol for an observational prospective cohort study of YOURS (YOu and Ulcerative colitis: Registry and Social network) Hajime Yamazaki, 1 Katsuyoshi Matsuoka,2 Jovelle Fernandez,3 Toshifumi Hibi,4 Mamoru Watanabe,5,6 Tadakazu Hisamatsu,7 Shunichi Fukuhara1 To cite: Yamazaki H, ABSTRACT Strengths and limitations of this study Matsuoka K, Fernandez J, et al. Introduction Ulcerative colitis (UC) is a chronic Ulcerative colitis outcomes inflammatory disease that mainly affects the colon in research in Japan: protocol for ► The YOu and Ulcerative colitis: Registry and Social young patients. Typical symptoms of UC are bloody an observational prospective network (YOURS) study is a large-scale, long-term, cohort study of YOURS (YOu diarrhoea and faecal urgency, which disturb the quality prospective observational study to explore optimal and Ulcerative colitis: Registry of life (QOL) of patients, and intractable UC leads to ulcerative colitis management for improving rele- and Social network). BMJ Open hospitalisation and colectomy. To improve relevant vant outcomes. 2019;9:e030134. doi:10.1136/ outcomes such as symptoms, QOL and colectomy, many ► The YOURS study reflects the real clinical setting bmjopen-2019-030134 clinical questions need to be resolved regarding what because any concomitant drugs and therapies are ► Prepublication history for the ideal lifestyle, psychosocial burden and optimal allowed. this paper is available online. practice patterns are. In this YOu and Ulcerative colitis: ► The YOURS study can be expanded for subsequent To view these files, please visit Registry and Social network (YOURS) study, we will surveys because patients and healthcare profes- the journal online (http:// dx. doi. investigate the effect of lifestyle, psychosocial factors and sionals can ask research questions not otherwise org/ 10. 1136/ bmjopen- 2019- practice patterns on patient-reported outcomes (PRO), included in the survey. 030134). hospitalisation rate and colectomy rate in Japanese ► Patients will be able to access their own data and compare them with summarised data from all pa- Received 28 February 2019 patients with UC. http://bmjopen.bmj.com/ Revised 22 July 2019 Methods and analysis For this prospective cohort tients on the website beyond the YOURS study. Accepted 01 August 2019 study, we recruited 2006 patients from five hospitals ► All investigational sites are located within one region (Tokyo and Chiba; May 2018–January 2019). Patients will of Japan, which may affect the study results, espe- be able to access their own data and compare them with cially because of lifestyle and psychosocial factors. summarised data from all patients on the website beyond the YOURS study. At baseline, patients will answer a questionnaire regarding lifestyle (diet, exercise, sleep and INTRODUCTION work), psychosocial factors (stress, depression and social Ulcerative colitis (UC) is a chronic inflam- on September 28, 2021 by guest. Protected copyright. support) and PRO (symptoms and QOL). Information matory disease with no curative treatment. on practice patterns (eg, medications, endoscopy frequency) will be collected from electronic medical It mainly affects the colon and is associated with bloody diarrhoea and faecal urgency records. Gaps between patients’ needs and healthcare 1 professionals’ practice will be identified. Follow-up as typical symptoms. Aberrant immunity surveys will be conducted periodically for approximately in the gut is considered to be involved in 2 3 years. Research questions suggested by patients and the pathogenesis of UC; however, the aeti- healthcare professionals may be used in subsequent ology of UC is not fully understood. UC is © Author(s) (or their surveys. Results from the YOURS study will demonstrate increasing around the world, especially in employer(s)) 2019. Re-use optimal UC management strategies to improve relevant Asia, including Japan.3–5 The prevalence of permitted under CC BY-NC. No commercial re-use. See rights outcomes. UC has been reported to range from 5.3 to and permissions. Published by ETHICS AND DISSEMINatiON 63.6 per 100 000 people in Asia and from 37.5 BMJ. 1 The study was approved by the ethics committees of five to 238 per 100 000 people in North America, For numbered affiliations see investigational sites before starting the study. The results and differs between regions, with the preva- end of article. will be submitted to journals. lence in Japan reported as approximately 100 per 100 000 people in 2013.5 Correspondence to TRIAL REGistratiON NUMBER The onset of UC often has a major influ- Hajime Yamazaki; UMIN000031995. yamazaki- myz@ umin. ac. jp ence on patients’ quality of life (QOL), and Yamazaki H, et al. BMJ Open 2019;9:e030134. doi:10.1136/bmjopen-2019-030134 1 Open access BMJ Open: first published as 10.1136/bmjopen-2019-030134 on 8 September 2019. Downloaded from Figure 1 Factors and outcomes assessed in the YOURS study. All four factors can contribute to all four outcomes. HCP, healthcare professional; YOURS, YOu and Ulcerative colitis: Registry and Social network. intractable UC can lead to hospitalisation and colec- Optimal disease monitoring and treatment need to be tomy. Patients need to manage UC throughout their lives clarified. with both self-management and support from health- The last challenge is gaps between patients’ needs and care professionals (HCPs) to avoid unwanted clinical HCPs’ practice. A previous survey has identified important outcomes, including relapse/exacerbation, hospital- differences between patients and HCPs in their percep- isation, and colectomy, as well as to improve patient-re- tion of the impact of UC symptoms on patients’ lives, ported outcomes such as QOL. suggesting that HCPs may underestimate the effect of UC In this YOURS (YOu and Ulcerative colitis: Registry and symptoms on patients.12 However, the effect of percep- Social network) study, we identified four main factors/ tion gaps on patient outcomes is unknown. challenges to the improvement of patient outcomes: (1) The YOURS study is an observational prospective lifestyle, (2) psychosocial factors, (3) practice patterns cohort study in patients with UC in Japan that aims to and (4) gaps between patients’ needs and HCPs’ practice clarify how these four challenges affect relapse/exacer- (figure 1). bation, hospitalisation, colectomy and patient-reported First, there has been much discussion and debate about outcomes such as QOL. http://bmjopen.bmj.com/ the optimal lifestyle (diet, exercise, sleep and work) for UC management. In particular, diet is a critical issue for both patients and their HCPs. Although a large-scale METHODS AND ANALYSIS study has reported that the relationship between diet and Study design relapse is of major interest to patients with inflammatory The YOURS study is an observational prospective cohort 6 bowel disease (IBD) and their HCPs, only two explor- study with a 3-year follow-up being conducted at five 7 8 atory studies have examined the relationship. However, investigational sites in Japan. Patient registration started the results from these studies were not consistent. in May 2018 and ended in January 2019. As of 11 January on September 28, 2021 by guest. Protected copyright. Second, psychosocial factors including stress, depres- 2019, 2006 patients have been enrolled. sion and social support may affect clinical outcomes in The study is being conducted in compliance with the UC. Approximately half of patients with IBD have low Declaration of Helsinki, Ethical Guidelines for Medical 9 QOL and depression, and one-third of patients are Research on Humans, Ministry of Education, Culture, 10 reported to feel stigmatised. It remains unknown how Sports, Science and Technology of Japan and Ministry these psychosocial factors affect disease course. of Health, Labour and Welfare of Japan and all appli- The third challenge is practice patterns. The Selecting cable laws and guidelines. Written informed consent will Therapeutic Targets in Inflammatory Bowel Disease be obtained from all patients. The study is registered at programme, published in 2015 by IBD specialists, recom- the University hospital Medical Information Network mends setting concrete treatment goals as part of a (UMIN) Center. ‘Treat to Target’ strategy.11 The agreed treatment goals for UC were clinical remission (defined as resolution of Study population and sample size rectal bleeding and diarrhoea/altered bowel habit) and Patients diagnosed with UC, as defined by the ‘Evidence- endoscopic remission (based on endoscopic findings). based Clinical Practice Guidelines for Inflammatory However, achievement of these treatment goals may be Bowel Disease’,5 who are ≥16 years of age at informed accompanied by decreased QOL due to frequent colo- consent and are attending the investigational sites are noscopies or side effects caused by immune suppression. eligible for enrolment. 2 Yamazaki H, et al. BMJ Open 2019;9:e030134. doi:10.1136/bmjopen-2019-030134 Open access BMJ Open: first published as 10.1136/bmjopen-2019-030134 on 8 September 2019. Downloaded from The sample size was determined by considering the validated questionnaires for most measures of lifestyle, feasibility of enrolling patients. psychosocial factors and symptoms. At the initial survey, patients will complete written Outcome measures and survey items questionnaires with demographic,
Load more

Recommended publications
  • Nilotinib in Patients with Chronic Myeloid Leukemia: STAT2 Trial in Japan
    Haematologica HAEMATOL/2018/194894 Version 3 Haematologica HAEMATOL/2018/194894 Version 3 Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan Naoto Takahashi, Kaichi Nishiwaki, Chiaki Nakaseko, Nobuyuki Aotsuka, Koji Sano, Chikako Ohwada, Jun Kuroki, Hideo Kimura, Michihide Tokuhira, Kinuko Mitani, Kazuhisa Fujikawa, Osamu Iwase, Kohshi Ohishi, Fumihiko Kimura, Tetsuya Fukuda, Sakae Tanosaki, Saori Takahashi, Yoshihiro Kameoka, Hiroyoshi Nishikawa, and Hisashi Wakita Disclosures: 1. This study was supported by research funding from Novartis Pharmaceuticals to N.T. 2. N.T reports grants from Novartis Pharmaceuticals, during the conduct of the study; grants and personal fees from Novartis Pharmaceuticals, grants and personal fees from Otsuka, grants and personal fees from Pfizer, personal fees from Bristol-Myers Squibb, outside the submitted work; K.N reports grants from Zenyaku Kogyo Company, Limited, grants from Chugai Pharmaceutical, grants from Novartis Pharma K.K., grants from Kyowa Hakko Kirin Co, Ltd, grants from Nippon Shinyaku Co, Ltd, outside the submitted work; C.N reports personal fees from Novartis, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Pfizer, grants and personal fees from Takeda pharmaceuticals, grants and personal fees from Kyowa Hakko Kirin, grants and personal fees from Otsuka Pharmaceutical, grants and personal fees from Ono Pharmaceutical, grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Asahi Kasei Pharma, grants and personal fees from Shionogi, personal fees from Shire, personal fees from Jannsen, personal fees from Celgene, outside the submitted work; M.T. reports personal fees from Bristol-Myers Squib, personal fees from Pfizer, outside the submitted work; K.M reports grants from Kyowa Hakko Kirin Co.
    [Show full text]
  • 1332 Nippon Suisan Kaisha, Ltd. 50 1333 Maruha Nichiro Corp. 500 1605 Inpex Corp
    Nikkei Stock Average - Par Value (Update:August/1, 2017) Code Company Name Par Value(Yen) 1332 Nippon Suisan Kaisha, Ltd. 50 1333 Maruha Nichiro Corp. 500 1605 Inpex Corp. 125 1721 Comsys Holdings Corp. 50 1801 Taisei Corp. 50 1802 Obayashi Corp. 50 1803 Shimizu Corp. 50 1808 Haseko Corp. 250 1812 Kajima Corp. 50 1925 Daiwa House Industry Co., Ltd. 50 1928 Sekisui House, Ltd. 50 1963 JGC Corp. 50 2002 Nisshin Seifun Group Inc. 50 2269 Meiji Holdings Co., Ltd. 250 2282 Nh Foods Ltd. 50 2432 DeNA Co., Ltd. 500/3 2501 Sapporo Holdings Ltd. 250 2502 Asahi Group Holdings, Ltd. 50 2503 Kirin Holdings Co., Ltd. 50 2531 Takara Holdings Inc. 50 2768 Sojitz Corp. 500 2801 Kikkoman Corp. 50 2802 Ajinomoto Co., Inc. 50 2871 Nichirei Corp. 100 2914 Japan Tobacco Inc. 50 3086 J.Front Retailing Co., Ltd. 100 3099 Isetan Mitsukoshi Holdings Ltd. 50 3101 Toyobo Co., Ltd. 50 3103 Unitika Ltd. 50 3105 Nisshinbo Holdings Inc. 50 3289 Tokyu Fudosan Holdings Corp. 50 3382 Seven & i Holdings Co., Ltd. 50 3401 Teijin Ltd. 250 3402 Toray Industries, Inc. 50 3405 Kuraray Co., Ltd. 50 3407 Asahi Kasei Corp. 50 3436 SUMCO Corp. 500 3861 Oji Holdings Corp. 50 3863 Nippon Paper Industries Co., Ltd. 500 3865 Hokuetsu Kishu Paper Co., Ltd. 50 4004 Showa Denko K.K. 500 4005 Sumitomo Chemical Co., Ltd. 50 4021 Nissan Chemical Industries, Ltd. 50 4042 Tosoh Corp. 50 4043 Tokuyama Corp. 50 WF-101-E-20170803 Copyright © Nikkei Inc. All rights reserved. 1/5 Nikkei Stock Average - Par Value (Update:August/1, 2017) Code Company Name Par Value(Yen) 4061 Denka Co., Ltd.
    [Show full text]
  • Toho Co., Ltd. Agenda
    License Sales Sheet October 2018 TOHO CO., LTD. AGENDA 1. About GODZILLA 2. Key Factors 3. Plan & Schedule 4. Merchandising Portfolio Appendix: TOHO at Glance 1. About GODZILLA About GODZILLA | What is GODZILLA? “Godzilla” began as a Jurassic creature evolving from sea reptile to terrestrial beast, awakened by mankind’s thermonuclear tests in the inaugural film. Over time, the franchise itself has evolved, as Godzilla and other creatures appearing in Godzilla films have become a metaphor for social commentary in the real world. The characters are no longer mere entertainment icons but embody emotions and social problems of the times. 2018 © TOHO CO., LTD. All rights reserved/ Confidential & Proprietary 4 About GODZILLA | Filmography Reigning the Kaiju realm for over half a century and prevailing strong --- With its inception in 1954, the GODZILLA movie franchise has brought more than 30 live-action feature films to the world and continues to inspire filmmakers and creators alike. Ishiro Honda’s “GODZILLA”81954), a classic monster movie that is widely regarded as a masterpiece in film, launched a character franchise that expanded over 50 years with 29 titles in total. Warner Bros. and Legendary in 2014 had reintroduced the GODZILLA character to global audience. It contributed to add millennials to GODZILLA fan base as well as regained attention from generations who were familiar with original series. In 2017, the character has made a transition into new media- animated feature. TOHO is producing an animated trilogy to be streamed in over 190 countries on NETFLIX. 2018 © TOHO CO., LTD. All rights reserved/ Confidential & Proprietary 5 Our 360° Business Film Store TV VR/AR Cable Promotion Bluray G DVD Product Exhibition Publishing Event Music 2018 © TOHO CO., LTD.
    [Show full text]
  • Hydrogen and Fuel Cells in Japan
    HYDROGEN AND FUEL CELLS IN JAPAN JONATHAN ARIAS Tokyo, October 2019 EU-Japan Centre for Industrial Cooperation ABOUT THE AUTHOR Jonathan Arias is a Mining Engineer (Energy and Combustibles) with an Executive Master in Renewable Energies and a Master in Occupational Health and Safety Management. He has fourteen years of international work experience in the energy field, with several publications, and more than a year working in Japan as an energy consultant. He is passionate about renewable energies, energy transition technologies, electric and fuel cell vehicles, and sustainability. He also published a report about “Solar Energy, Energy Storage and Virtual Power Plants in Japan” that can be considered the first part of this document and is available in https://lnkd.in/ff8Fc3S. He can be reached on LinkedIn and at [email protected]. ABOUT THE EU-JAPAN CENTRE FOR INDUSTRIAL COOPERATION The EU-Japan Centre for Industrial Cooperation (http://www.eu-japan.eu/) is a unique venture between the European Commission and the Japanese Government. It is a non-profit organisation established as an affiliate of the Institute of International Studies and Training (https://www.iist.or.jp/en/). It aims at promoting all forms of industrial, trade and investment cooperation between the EU and Japan and at improving EU and Japanese companies’ competitiveness and cooperation by facilitating exchanges of experience and know-how between EU and Japanese businesses. (c) Iwatani Corporation kindly allowed the use of the image on the title page in this document. Table of Contents Table of Contents ......................................................................................................................... I List of Figures ............................................................................................................................ III List of Tables ..............................................................................................................................
    [Show full text]
  • Industrial Report (C) JETRO Japan Economic Monthly, August 2005
    Industrial Report (C) JETRO Japan Economic Monthly, August 2005 Trends in the Pharmaceutical Industry Japanese Economy Division Summary The nature of Japan’s pharmaceutical market is changing. The market for generic drugs in Japan has been expanding in recent years. Major Japanese pharmaceutical companies have undertaken mergers and restructuring, and an increasing number of foreign pharmaceutical companies have entered the Japanese market recently by establishing joint ventures with Japanese drug companies or granting distribution rights for their products to Japanese firms. 1. Market Overview The Japanese pharmaceutical industry, buoyed by a rise in income levels and growing awareness about hygiene after World War II, has grown gradually in line with Japanese industry. The introduction of universal health insurance coverage in April 1961 triggered a soaring increase in domestic demand for medicines. The brisk development of new medicines based on technologies introduced from the West has enabled the industry to respond more quickly to market needs. As a result, the Japanese pharmaceutical industry is now second only to that of the United States. In recent years, however, Fig. 1-1 Japanese Market Share of Generic Drugs (GE/total drugs) the financial situation (%) Value Quantity basis surrounding health insurance has (Drug price basis) become strained due to increasing 1999 4.7 10.8 medical costs shouldered by the 20024.8 12.2 2003 5.2 16.4 government, owing to the aging Source: Japan Generic Pharmaceutical Manufacturers Association population, advances in medical Fig. 1-2 Market Shares of Generic Drugs in Main Countries technology and the development (2002) of new medical equipment.
    [Show full text]
  • 『Summary of Activities for Hydrogen Utilization in Chubu in 2030』
    1 『Summary of Activities for Hydrogen Utilization in Chubu in 2030』 February 19th, 2021 Hydrogen Utilization Study Group in Chubu ■ Eleven private companies which are promoting hydrogen utilization (listed below) have established the Hydrogen Utilization Study Group in Chubu in March 2020 to expand hydrogen demand and to build a supply chain for stable hydrogen utilization in the Chubu region. ■ This Group takes its first effort in Japan to conduct cross-sectional studies in various industries such as energy (oil, gas and electricity), petrochemicals, automobiles, steel manufacturing and finance. <Participating Companies＞ Alphabetically, ♦Secretariat companies Air Liquide Japan G.K. /Chubu Electric Power Co., Inc. /ENEOS Holdings, Inc. / Idemitsu Kosan Co., Ltd /Iwatani Corporation / Mitsubishi Chemical Corporation/ Nippon Steel Corporation /Sumitomo Corporation♦/Sumitomo Mitsui Banking Corporation♦/ Toho Gas Co., Ltd. /Toyota Motor Corporation♦ Hydrogen Utilization Study Group in Chubu 【Summary】 2 ＜Background of Study＞ On December 26, 2017, Ministry of Economy, Trade and Industry (hereinafter “METI”) published the Basic Hydrogen Strategy which included the following targets. ▽Realization of low-cost hydrogen usage under the Basic Strategy in order to move towards a hydrogen-based society: ■ As a basic approach, procurement of hydrogen at large scale, either by i) use of combination of inexpensive, unused energy of overseas markets with CCS, or ii) use of inexpensive, renewable energy to be used by electrolysis ■ Realization of annual procurement of 300 Kt/y of hydrogen, by developing commercial-scale supply chains by around 2030. Aim to realize hydrogen cost of 30 JPY/Nm3. ■ In the later phase, further endeavor to lower the hydrogen cost to 20 JPY/Nm3 to allow hydrogen to gain the same competitiveness as traditional energy sources after environmental cost adjustments are incorporated.
    [Show full text]
  • Nber Working Paper Series Did Mergers Help Japanese
    NBER WORKING PAPER SERIES DID MERGERS HELP JAPANESE MEGA-BANKS AVOID FAILURE? ANALYSIS OF THE DISTANCE TO DEFAULT OF BANKS Kimie Harada Takatoshi Ito Working Paper 14518 http://www.nber.org/papers/w14518 NATIONAL BUREAU OF ECONOMIC RESEARCH 1050 Massachusetts Avenue Cambridge, MA 02138 December 2008 The paper started as a joint project with Dr. Kelly Wang when she was Assistant Professor at University of Tokyo. The authors are grateful to her for her help in providing us with computer programs and in discussion the ways to apply her methods to the Japanese banking data. Upon Dr. Wang's departure from the University of Tokyo, the project was carried on by the current two authors with full consent from Dr. Wang. The current two authors take responsibility for any remaining errors. Mr. Shuhei Takahashi provided us with superb research assistance. We are grateful for financial support from Nomura foundation for social science and Chuo University for Special Research. We are also grateful for helpful discussions with Masaya Sakuragawa, Naohiko Baba, Satoshi Koibuchi, Woo Joong Kim, Joe Peek, Kazuo Kato and for insigutful comments from participants in Asia pacific Economic Association in Hong Kong in 2007, Japan Economic Association in 2008, NBER Japan Group Meeting in 2008 and Asian FA-NFA 2008 International Conference. The views expressed herein are those of the author(s) and do not necessarily reflect the views of the National Bureau of Economic Research. NBER working papers are circulated for discussion and comment purposes. They have not been peer- reviewed or been subject to the review by the NBER Board of Directors that accompanies official NBER publications.
    [Show full text]
  • 10/27[Thu] Press Daily Schedule
    10/27[THU] PRESS DAILY SCHEDULE TOHO Cinemas Roppongi Press Starting Ending NO. Section Title Venue Event Sign-in Guests (Tentative) Contact Info. Time Time Time Rikiya Imaizumi(Director), Koji Ichihashi(Producer), Taro Uchibori(Actor), Marika Matsumoto(Actress), Masaru TOHO CINEMAS Yahagi(Actor), Miki Akiba(Actress), Hachi Nekome(Actress), Yui TIFF Public Relations Group 1 Japanese Cinema Splash Same Old, Same Old Stage Appearance 9:30 10:20 10:35 ROPPONGI SC8 Murata(Actress), Kento Hikita(Actor), Ayaka Kawashima(Actress), +81 3 6226 3012 Mari Koike(Actress), Mao Yasuda(Actress), Chiharu Mimori(Actress), Ayano Kaneko(Theme Song) TOHO CO., LTD. TOHO CINEMAS Makoto Shinkai(Original Novel/Screenplay/Director), Yojiro Yasuhiro Toyosawa 3 Japan Now your name. Q&A 11:55 12:22 12:52 ROPPONGI SC1 Noda(RADWIMPS) +81 3 3591 3511 [email protected] TOHO CINEMAS Rikiya Imaizumi(Director), Koji Ichihashi(Producer), Taro TIFF Public Relations Group 2 Japanese Cinema Splash Same Old, Same Old Q&A 12:30 12:57 13:27 ROPPONGI SC8 Uchibori(Actor) +81 3 6226 3012 TOHO CINEMAS Jun Robles Lana(Director/Producer/Original Story), Paolo TIFF Public Relations Group 4 Competition Die Beautiful Press Conference 12:30 13:00 13:30 ROPPONGI SC6 Ballesteros(Actor), Perci Intalan(Executive Producer) +81 3 6226 3012 Sony Music Artists inc. Takeo Kikuchi(Director), Minori Hagiwara(Actress), Sayu TOHO CINEMAS Waka Uchida 5 Japanese Cinema Splash Hello, Goodbye Stage Appearance 13:45 14:35 14:50 Kubota(Actress), Masako Motai(Actress), Shunsuke ROPPONGI SC3 +81 3 5414 7351 Watanabe(Actor/ Music) [email protected] 76 Minutes and 15 Seconds TOHO CINEMAS TIFF Public Relations Group 7 World Focus with Abbas Kiarostami / Q&A 14:45 15:12 15:42 Seifollah Samadian(Director/Cinematographer/Editor/Producer) ROPPONGI SC7 +81 3 6226 3012 Take Me Home Sony Music Artists inc.
    [Show full text]
  • Press Release August 6Th, 2021 Sumitomo Corporation Chiyoda Corporation Toyota Motor Corporation Japan Research Institute, Ltd. Sumitomo Mitsui Banking Corporation
    Press Release August 6th, 2021 Sumitomo Corporation Chiyoda Corporation Toyota Motor Corporation Japan Research Institute, Ltd. Sumitomo Mitsui Banking Corporation Feasibility Study on the receiving and distribution business of imported hydrogen in Chubu Region Sumitomo Corporation (Head Office: Chiyoda-ku, Tokyo; Representative Director, President and Chief Executive Officer: Masayuki Hyodo), Chiyoda Corporation (Head Office: Yokohama City, Kanagawa Prefecture; President & COO : Masaji Santo), Toyota Motor Corporation (Head Office: Toyota City, Aichi Prefecture; President and Representative Director : Akio Toyoda), Japan Research Institute, Limited (Head Office: Shinagawa-ku, Tokyo; Representative Director, President and CEO: Katsunori Tanizaki), and Sumitomo Mitsui Banking Corporation (Head Office: Chiyoda-ku, Tokyo; President and CEO: Makoto Takashima) (collectively, “Joint Contractors”) have been appointed by the New Energy and Industrial Technology Development Organization ("NEDO") to conduct a feasibility study on the receiving and distribution business of hydrogen in Chubu Region ("Study"). NEDO selected the Joint Contractors in the public offeriing for "Development of Technologies for Realizing a Hydrogen Society/Regional Hydrogen Utilization Technology Development/Hydrogen Production and Utilization Potential Research" and the Study is scheduled to be conducted during FY2021 and FY2022. In order to promote the utilization of hydrogen in Japan, it is essential not only to produce hydrogen domestically, but also to import large volumes of hydrogen from cost competitive areas. To materialize large volume of imports, it is important to build supply chains from import terminals to demand locations, and to put priority on identifying challenges and find its solutions. Building on the previous study of potential hydrogen demand in Chubu region by the Hydrogen Utilization Study Group (“Study Group”) conducted in February 2021, this Study will focus on developing a large-scale hydrogen supply chain.
    [Show full text]
  • Introduction
    Hypertension Research (2014) 37, 256–259 & 2014 The Japanese Society of Hypertension All rights reserved 0916-9636/14 www.nature.com/hr GUIDELINES (JSH 2014) Introduction Hypertension Research (2014) 37, 256–259; doi:10.1038/hr.2014.18 The Japanese Society of Hypertension revised the Japanese Society of JSH 2014 should also be used by health nurses, nurses, dietitians and Hypertension Guidelines for the Management of Hypertension in staff responsible for team practice for hypertension management. 2009 (JSH 2009) and published the JSH 2014. Basically, the JSH 2014 Therefore, in addition to specialists in hypertension, the members of was prepared according to strategies to prepare the JSH 2009 and the The Japan Association of Medical Practitioners, The Japanese Society ‘Guidance for the Preparation of Treatment Guidelines in 2007’ of Clinical Pharmacology and Therapeutics, Japan Pharmaceutical established by the Medical Information Network Distribution Service. Association, Japanese Society of Clinical Nutrition, and Patient In the ‘Introduction’ section, methods to prepare the JSH 2014 are Corporation belong to the Japanese Society of Hypertension Com- introduced. mittee for Guidelines for the Management of Hypertension. With regard to the affiliations of the committee members, their occupation, 1. OBJECTIVE AND SUBJECTS OF THE JSH 2014 affiliated corporations and positions are described. Hypertension causes stroke (cerebral infarction, cerebral hemorrhage, subarachnoidal hemorrhage), heart disease (coronary artery disease, 2. COMPOSITION OF THE JAPANESE SOCIETY OF cardiac hypertrophy, heart failure), kidney disease (nephrosclerosis) HYPERTENSION COMMITTEE FOR GUIDELINES FOR THE and macrovascular disease. Therefore, the primary objective MANAGEMENT OF HYPERTENSION of the JSH 2014 is to present standard treatment to prevent the The Japanese Society of Hypertension Guidelines for the Management onset/progression of hypertensive complications of the brain/heart/ of Hypertension is official.
    [Show full text]
  • Annual Report 2016 for the Year Ended December 31, 2016
    Annual Report 2016 For the year ended December 31, 2016 Leaping Forward Contents Review of Operations Editorial Policy 02 (Contents/Editorial Policy) 18 (Pharmaceuticals Business/Bio-chemicals Business) This is our Annual Report for 2016. The environment surrounding the pharmaceuticals industry is rapidly changing, and there Our Philosophy Corporate Governance is a movement to dramatically revise the framework that has (Management Philosophy/Core Values) (Board of Directors/Corporate Governance) 03 31 underpinned the industry thus far. Despite this environment, “human resources” and “technology” will continue to be the Who we are Compliance baseline for innovation at Kyowa Hakko Kirin Group, which 04 (Group Structure/Business Model) 35 (Compliance/Risk Management) aspires to realize health and well-being. In the special features, we describe our human resource development that is promoting our globalization and our production technology for biopharmaceuticals. Niro Sakamoto, Executive Officer, Director of What we do Dialogue Please deepen your understanding of our group, which is taking Corporate Communications 06 (FY2016-2020 Mid-term Business Plan) 38 (Vice President × Outside Directors) initiatives to make the leap forward to become a Global Specialty Department Pharmaceutical Company (GSP). High Top Message Financial Information 07 41 Importance to Stakeholders Annual Report (PDF version) http://ir.kyowa-kirin.com/en/library/annual_report.html Special Feature Kyowa Hakko Kirin Website Special Feature 1: Human Resource Development Investor
    [Show full text]
  • Pasetocin and Sawacillin
    Pasetocin® and Sawacillin®: Joint Application Seeking Approval for Additional Indication for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitors and either Clarithromycin or Metronidazole Tokyo, August 31, 2012 - Kyowa Hakko Kirin Co., Ltd. (“Kyowa Hakko Kirin”; Tokyo:4151; President and CEO: Nobuo Hanai) and Astellas Pharma Inc. (“Astellas Pharma”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced today that they have submitted a joint application* to Japan’s Ministry of Health, Labour and Welfare seeking approval of Helicobacter pylori (“H. pylori”) gastritis as an additional indication for H. pylori eradication by triple therapy including amoxicillin hydrate (generic name; brand names: “Pasetocin® Capsules 125 and 250; Pasetocin® Tablets 250”, “Sawacillin® Capsules 125 and 250; Sawacillin® Tablets 250” and one other brand). This concomitant therapy consists of a proton pump inhibitor (lansoprazole, omeprazole, rabeprazole sodium and esomeprazole magnesium hydrate, generic name; marketed under five brand names), amoxicillin hydrate, and either clarithromycin (generic name; marketed under two brand names) or metronidazole (generic name; marketed under one brand name). H. pylori gastritis is also known as chronic active gastritis due to the fact that it causes histological gastric mucosal injury as a result of the persistent infiltration of inflammatory cells in the gastric mucosa due to H. pylori infection, and is believed to be associated with the development of various H. pylori-related diseases such as gastric and duodenal ulcers. However, under the Japanese National Health Insurance (NHI) system, the approved indications for eradication of H. pylori are currently limited to gastric and duodenal ulcers, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and the stomach after endoscopic resection of early stage gastric cancer.
    [Show full text]